APM
RNAM

Avidity Partners Management’s Avidity Biosciences RNAM Stock Holding History

Avidity Partners Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,265,545
Closed -$19.4M – 106
2023
Q1 		$19.4M Sell
1,265,545
-2,009,455
-61% -$44.2M 0.64% 51
2022
Q4 		$72.7M Buy
3,275,000
+675,000
+26% +$10.1M 1.57% 22
2022
Q3 		$42.5M Buy
2,600,000
+519,800
+25% +$9.94M 0.86% 37
2022
Q2 		$30.2M Buy
2,080,200
+35,200
+2% +$524K 0.69% 35
2022
Q1 		$37.8M Buy
2,045,000
+230,000
+13% +$3.91M 0.79% 38
2021
Q4 		$43.1M Buy
1,815,000
+170,000
+10% +$4.06M 0.92% 36
2021
Q3 		$40.5M Buy
+1,645,000
New +$35.8M 0.9% 39
2020
Q3 		– Sell
-234,814
Closed -$6.64M – 84
2020
Q2 		$6.64M Buy
+234,814
New +$6.77M 0.43% 51

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Avidity Partners Management's RNAM Position: Q2 2023 in Review

Avidity Partners Management sold out of Avidity Biosciences (RNAM) in Q2 2023, closing a stake of 1,265,545 shares — an estimated $19.4M sold.

Avidity Partners Management first reported a position in RNAM in Q2 2020 and held it in 8 quarters. The position peaked at $72.7M in Q4 2022. 143 funds tracked by Wall St. Rank hold RNAM as of Q2 2023.

  • Avidity Partners Management reported no remaining Avidity Biosciences position as of Q2 2023 after selling out during the quarter.
  • Avidity Partners Management sold 1,265,545 Avidity Biosciences shares in Q2 2023, an estimated $19.4M.
  • Avidity Partners Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 8 quarters.
  • Avidity Partners Management's Avidity Biosciences position peaked at $72.7M in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2023.

Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.